XNCR Quote, Financials, Valuation and Earnings

Nektar Therapeutics has a net margin of -86.29% compared to Xencor's net margin of 24.89%. Xencor's return on equity of -35.99% beat Nektar Therapeutics's return on equity of -133.07%.

Xencor has a consensus price target of $30.30, signalling upside risk potential of 188.3%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 534.33%. Given that Nektar Therapeutics has higher upside potential than Xencor, analysts believe Nektar Therapeutics is more attractive than Xencor.

Xencor has a beta of 0.900, which suggesting that the stock is 10.041% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.381%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $52.8M, which are larger than Nektar Therapeutics quarterly revenues of $29.2M. Xencor's net income of -$45.6M is lower than Nektar Therapeutics's net income of $7.3M. Notably, Xencor's price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 6.19x versus 1.62x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -86.29% compared to Xencor's net margin of --. Xencor's return on equity of -35.99% beat Plus Therapeutics's return on equity of --.

Xencor has a consensus price target of $30.30, signalling upside risk potential of 188.3%. On the other hand Plus Therapeutics has an analysts' consensus of $9.63 which suggests that it could grow by 1121.6%. Given that Plus Therapeutics has higher upside potential than Xencor, analysts believe Plus Therapeutics is more attractive than Xencor.

Xencor has a beta of 0.900, which suggesting that the stock is 10.041% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.459%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $52.8M, which are larger than Plus Therapeutics quarterly revenues of --. Xencor's net income of -$45.6M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Xencor's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 6.19x versus 0.97x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -86.29% compared to Xencor's net margin of -80.9%. Xencor's return on equity of -35.99% beat Ultragenyx Pharmaceutical's return on equity of -194.36%.

Xencor has a consensus price target of $30.30, signalling upside risk potential of 188.3%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $91.80 which suggests that it could grow by 141.01%. Given that Xencor has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Xencor is more attractive than Ultragenyx Pharmaceutical.

Xencor has a beta of 0.900, which suggesting that the stock is 10.041% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.255%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $52.8M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $164.9M. Xencor's net income of -$45.6M is higher than Ultragenyx Pharmaceutical's net income of -$133.4M. Notably, Xencor's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 6.19x versus 6.15x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -86.29% compared to Xencor's net margin of 24.22%. Xencor's return on equity of -35.99% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Xencor has a consensus price target of $30.30, signalling upside risk potential of 188.3%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $850.21 which suggests that it could grow by 41.08%. Given that Xencor has higher upside potential than Regeneron Pharmaceuticals, analysts believe Xencor is more attractive than Regeneron Pharmaceuticals.

Xencor has a beta of 0.900, which suggesting that the stock is 10.041% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Xencor pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $52.8M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Xencor's net income of -$45.6M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Xencor's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 15.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 6.19x versus 4.88x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.